key: cord-0994299-rd1grlid
authors: Jourdain, M.; Benchaib, M.; Ploin, D.; Javouhey, E.; Horvat, C.; Massoud, M.; Butin, M.; Claris, O.; Lina, B.; VRS study group in Lyon,; Casalegno, j.-s.
title: Identifying the target population for primary Respiratory Syncytial Virus two-step prevention in infants: Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN)
date: 2022-02-15
journal: nan
DOI: 10.1101/2022.02.08.22270569
sha: c6997af7b8afd7ad11ce92efedb9218d567a356c
doc_id: 994299
cord_uid: rd1grlid

Background: Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection related hospitalisations in infants (RSVh). Most of these infants are younger than 6 months old with no known risk factors. An efficient RSVh prevention program should address both mothers and infants, relying on Non-Pharmaceutical (NPI) and Pharmaceutical Interventions (PI). This study aimed at identifying the target population for these two interventions. Methods: Laboratory-confirmed RSV-infected infants hospitalised during the first 6 months of life were enrolled from the Hospices Civils de Lyon birth cohort (2014 to 2018). Clinical variables related to pregnancy and birth (sex, month of birth, birth weight, gestational age, parity) were used for descriptive epidemiology, multivariate logistic regression, and predictive score development. Findings: Overall, 616 cases of RSVh in 45 648 infants were identified. Being born before the epidemic season, prematurity, and multiparity were independent predictors of RSVh. Infants born in January or June to August with prematurity and multiparity, and those born in September or December with only one other risk factor (prematurity or multiparity) were identified as moderate-risk, identifying the mothers as candidates for a first level NPI prevention program. Infants born in September or December with prematurity and multiparity, and those born in October or November were identified as high-risk, identifying the mothers and infants as candidates for a second level (NPI and PI) intervention. Interpretation: It is possible to determine predictors of RSVh at birth, allowing to enrol early the target population in a two-level RSV prevention intervention.

Predictive models can help adjust the preventive action to the target population. 17 Regarding 110 the risk of RSV-associated hospitalisation (RSVh), most of the published predictive models 111 have focused on high risk preterm infants. 18 Overall, 45 648 infants were included in the study (2014 to 2018) from a catchment area of 152 1,370,678 inhabitants using public hospital registry data from the HCL (Figure 1 ). 26 To ensure 153 the stability of the score, the population studied was divided into three cohorts. The validating 154 cohort was defined as the 2018 birth cohort (n=8 709 infants born between January 2018 and 155

December 2018). The remaining cohort (2014 to 2017) was then randomly divided, with 156 equal-sized month of birth proportion, into a training cohort (70% of the remaining cohort, n= 157 25 858) and a testing cohort (30% of the remaining cohort, n=11 081). The validating cohort 158 was exposed to the 2018/2019 RSV season which was similar to the previous epidemics 27 159 (Table 1) . 160 161 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.08.22270569 doi: medRxiv preprint 8/24

To identify potential independent maternal RSVh predictors, all variables of the training 163 cohort were entered into a multivariate backwards stepwise logistic regression model to 164 remove predictors that did not significantly improve the fit of the logistic regression model 165 (based on a p-value of 0•10). The odds ratio (OR) values obtained from the final model were 166 rounded to the nearest integer and used to determine the score. The model was adjusted with 167 the year of birth and the hospital of birth (Table 2) . 168

To evaluate the optimism-corrected performance values, the real-life model's performance 171 was quantified using the area under the receiver operating characteristic curve (AUROC) 172 (with 95% confidence interval) and the Brier score in the testing and validating cohorts. A k-173 fold (with k=4) cross validation approach was used to estimate the model's variance on the 174 training cohort. The distribution of month of birth was preserved in the split training sets 175 obtained using the k-fold cross validation. The validating cohort corresponds to a new set of 176 infants exposed to a new RSV epidemic and was used as an external control. 177

In the absence of any similar predictive model but based on references from research on other 178 medical predictive models, and given the potential cost-effectiveness of the preventive 179 program, an AUROCC ≥ 0•70 was considered as evidence for good discrimination. 28,29 A test 180 was considered significant when p value was lower than 0•05. 181 182 Determining the cut-off values of the two-level preventive program 183

The optimal cut-off value for the first level of intervention (NPI alone) was defined a priori 184 with minimal sensitivity and specificity values of 80 % and 20%, respectively. This cut-off 185 assumed a lower cost and effectiveness for NPI compared to PI. However, an NPI preventive 186 program may not be maintained all year-round if the perceived risk is too low. This 187 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 15, 2022. The optimal cut-off value for the second level of intervention (NPI and PI) was defined a 190 priori with a minimal specificity value of 80%. This cut-off assumed a higher cost and 191 effectiveness for PI that would be then more suitable for a timely seasonal administration than There was no funding source for this study. The corresponding author had full access to all 212 the data in the study and had the final responsibility for the decision to submit for publication. 213 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) (Table 1) . Among all cases, 0•8% (5) were suspected to be 225 nosocomial. The characteristics of the testing and training cohorts did not significantly differ. 226

The validating cohort did not significantly differ in terms of mean WG and birth weight when 227 compared to the testing and training cohorts. Significant differences in the frequencies of 228 month of birth, parity, gestation type, and childbirth type were observed between the 229 validating cohort and the testing and training cohorts (Table 1) Figure 2) . 243

In the model analysis, the month of birth was aggregated into these four groups of respective 244

increased RSVh incidence. The choice to aggregate this variable was done to facilitate the 245 implementation of the score in the patient and healthcare community in the context of 246 pregnancy. 247 248

The multivariate logistic regression analysis in the training cohort retrieved three variables 250 significantly associated with hospitalisation: month of birth, gestational age, and parity. Table 2 The optimal cut-off values of the RSVh predictive score for the first and second levels of 272 intervention were 14 and 28, respectively. The maternal population with an RSVh predictive 273 score below the first cut-off value (14) of intervention was defined as a low-risk group (Table  274 3). It encompasses all the mothers giving birth during the months of February to May and the 275 deliveries occurring during the months of January or June to August with no more than one 276 risk factor (prematurity or multiparity). 277

The maternal population with an RSVh predictive score above the first cut-off value (> 14) 278 and below the second cut-off value (< 28) of intervention was defined as a moderate-risk 279 group. It encompasses the deliveries occurring during the months of January or June to 280

August with prematurity and multiparity and the deliveries in September or December with 281 only one other risk factor (prematurity or multiparity). 282

The maternal population with an RSVh predictive score above the second cut-off value (> 28) 283 was defined as a high-risk group. It encompasses the deliveries in September or December 284 with prematurity and multiparity and all deliveries in October or November (Table 3) . 285

When applied to the validating cohort, the predictive score identified 53% of infants as low-286 risk (incidence 1•72 cases /1000 infants), 32% of infants as moderate-risk (incidence 287 18•92/1000 infants), and 15% of infants as high-risk (incidence 46•28/1000 infants; Table 3 ). 288 289 Discussion 290 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.08.22270569 doi: medRxiv preprint

In the present study, an original but simple approach was used to identify the target 291 population for a two-level preventive mother-infant intervention program based on maternal 292 and newborn risk factors. 293

The clinical predictors identified herein were already described in previous reports. 19-21 294 Month of birth is by far the strongest predictor of RSVh in the general birth cohort. This 295 finding is consistent with numerous previous observations reporting that infants born before 296 the RSV peak month have the highest RSVh admission rates. 33 Prematurity under 37 WG and 297 multiparity were also previously associated with increased RSVh risk. 34,35 298 The present approach differs from other RSVh prediction models. [19] [20] [21] [22] The novelty herein is 299 the use of RSVh risk factors that can be identified early in the pregnancy (month of birth and 300 multiparity) or at the infant's birth (WG). It allows the inclusion of target mothers and then 301 infants in a prevention program tailored to the infant's risk of RSVh. The first level entails a 302 reinforced behaviour change program (BCP) to promote good hygiene practices (hand 303 hygiene, breastfeeding, avoiding exposure to smoke and persons with acute respiratory 304 illness) and education on bronchiolitis. The second level is a pharmaceutical prevention 305 program that will integrate future licensed preventive drug interventions. These BCP and PI 306 can be introduced early during pregnancy follow-up so that the different healthcare workers 307 involved in the pregnancy, childbirth, and postnatal periods can repeatedly promote them to 308 the target population. 309

A major strength of this study was that all the diagnoses were PCR-confirmed, with only 310 minor missing values. Indeed, identifying cases based on diagnosis codes, such as admissions 311 for bronchiolitis, is neither fully specific nor sensitive. On one hand, bronchiolitis can be 312 caused by other respiratory viruses such as rhinoviruses, metapneumoviruses, and 313

influenzaviruses. 36 On the other hand, RSV admissions could be related to disease codes other 314 than bronchiolitis (sepsis, acute otitis). According to the hospital's local protocol, all infants 315 below the age of 1 year old hospitalised with acute respiratory infection, are tested for RSV 316 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.08.22270569 doi: medRxiv preprint 14/24 during the RSV epidemic season. 24 A sensitivity analysis performed over one RSV season 317 (2016/2017) showed that 83•4% of all hospitalisations for bronchiolitis were due to RSV 318 (PCR-confirmed), while 11•5% were related to other viruses (5% did not have any sample 319 tested) 37 . The second major strength of this work is that a complete case analysis was 320 performed, as there was only a small proportion of infants excluded for missing data. In 321 addition, dividing the population studied into three cohorts allowed a robust estimation of the 322 score's performance. 323

There are, however, some limitations to this work. First, the cost-effectiveness of the future 324 licensed preventive treatments remains to be determined. One consequence of the COVID-19 325 crisis may be a better integration and promotion of NPI in the prevention of viral respiratory 326 diseases. Although more costly, the future drugs in development will likely represent a more 327 efficient preventive approach if dedicated to high-risk infants. Therefore, this two-step 328 strategy is likely to be considered in the near future. Another limitation is that some known 329 risk factors (exposure to smoke, parent's education level, mother's age) 38 were not present in 330

the database and therefore not tested in the model. Palivuzimab use was also not measured in 331 this study. According to the French guidelines, Palivuzimab is recommended for premature 332 babies born before 29 WG or born before 32 WG with risk factors. This did not represent 333 more than 2% of the present birth cohort. Given that extremely premature infants are a small 334 subgroup of the general population, and that extreme prematurity was still a higher risk factor 335 than preterm and term births, it was assumed that the general model was not significantly 336 affected by the use of Palivizumab. 337

Using a hospital birth cohort, the NOHAN strategy allowed to determine strong maternal and 338 newborn predictors of RSVh risk. By using this strategy, future parents could be enrolled 339 early during pregnancy follow-up in a health-related BCP. The pregnant women could then be 340 proposed a vaccine boost, or neutralizing monoclonal antibodies could be administered to the 341 newborns. As demonstrated herein, the thresholds for triggering each level of intervention can 342 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.08.22270569 doi: medRxiv preprint 19/24 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.08.22270569 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

Respiratory syncytial virus: the virus, the disease and the immune response

The burden of respiratory syncytial virus 398 infection in young children

Global, regional, and national disease burden 400 estimates of acute lower respiratory infections due to respiratory syncytial virus in young 401 children in 2015: a systematic review and modelling study

The clinical and health economic burden of respiratory 403 syncytial virus disease among children under 2 years of age in a defined geographical area

Burden of 406 hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: A 407 data linkage modelling study

Review of epidemiology and clinical risk factors for severe respiratory 409 syncytial virus (RSV) infection

Risk factors for hospital admission with RSV 411 bronchiolitis in England: a population-based birth cohort study

The contribution of child, 414 family and health service factors to respiratory syncytial virus (RSV) hospital admissions 415 in the first 3 years of life: birth cohort study in Scotland

Strategies for reducing the risk of 418 respiratory syncytial virus infection in infants and young children: a Canadian nurses' 419 perspective

Characteristics of the delayed respiratory 421 syncytial virus epidemic

The impact of 424 COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections

Immunoprophylaxis with palivizumab, a 427 humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory 428 syncytial virus infection in high risk infants: a consensus opinion

Respiratory Syncytial Virus Vaccination during 431 Pregnancy and Effects in Infants

Single-Dose Nirsevimab for Prevention of RSV in 433 Preterm Infants

Approaching the End of the Era of Uncontrolled Respiratory Syncytial 435 Virus Disease

Assessment and optimization of respiratory syncytial 437 virus prophylaxis in Connecticut

The respiratory syncytial virus vaccine landscape: 439 lessons from the graveyard and promising candidates

Prediction models: the right tool for the right problem

A predictive model for respiratory 444 syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of 445 gestational age, based on data from the Spanish FLIP Study

Development and validation of a risk 447 scoring tool to predict respiratory syncytial virus hospitalization in premature infants born 448 at 33 through 35 completed weeks of gestation

Risk-Scoring Tool for respiratory syncytial virus 450 prophylaxis in premature infants born at 33-35 completed weeks

Prospective validation of a prognostic model for respiratory syncytial virus 454 bronchiolitis in late preterm infants: a multicenter birth cohort study

Clinical prediction rule for RSV bronchiolitis in 457 healthy newborns: prognostic birth cohort study

Cost and burden of 459 RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon

National, regional, and worldwide 462 estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected 463 countries: a systematic analysis and implications

Évolution et structure de la population en 2015 − Population en 2015 | Insee

Economic and disease burden of RSV-associated 467 hospitalizations in young children in France

Principles and practical application of the receiver-470 operating characteristic analysis for diagnostic tests

Index for rating diagnostic tests

CoviPrev : une enquête pour suivre l'évolution des comportements et de la santé mentale 473 pendant l'épidémie de COVID-19

Cost-effectiveness of strategies for preventing paediatric 477 lower respiratory infections associated with respiratory syncytial virus in eight Chinese 478 cities

Risk factors 480 for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life

Hospital Admissions and Bed Days in Children <5 Years of Age in 7 European Countries

Hospitalization for respiratory syncytial 486 virus infection in young children: development of a clinical prediction rule

Risk factors for severe RSV-induced lower 489 respiratory tract infection over four consecutive epidemics

Association of rhinovirus infection with 492 increased disease severity in acute bronchiolitis

Family and Child Risk Factors for Early-Life 500 RSV Illness